Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá

Introducción: La Leucemia Linfoide Aguda (LLA) es el cáncer más común en niños. Existen estudios de sobrevida y sus factores asociados en países de altos ingresos, pero pocos en países de ingreso mediano-alto, como Colombia. Objetivo: Establecer la sobrevida global y analizar los factores que incide...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2021
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
spa
OAI Identifier:
oai:repository.urosario.edu.co:10336/30971
Acceso en línea:
https://doi.org/10.48713/10336_30971
https://repository.urosario.edu.co/handle/10336/30971
Palabra clave:
Leucemia Linfoide Aguda (LLA) en niños
Estudios de sobrevida a la LLA en países de ingreso mediano-alto
Estimación de curvas de sobrevida con el método Kaplan-Meier
Enfermedades
Acute Lymphoid Leukemia (ALL) in Children
Survival studies for ALL in upper-middle-income countries
Estimation of survival curves with the Kaplan-Meier method
Rights
License
Atribución-SinDerivadas 2.5 Colombia
id EDOCUR2_e319f0ad18dcb6df29c12348643d9e3e
oai_identifier_str oai:repository.urosario.edu.co:10336/30971
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
dc.title.TranslatedTitle.spa.fl_str_mv Survival and associated factors in children with Acute Lymphoid Leukemia in a reference center in Bogotá
title Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
spellingShingle Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
Leucemia Linfoide Aguda (LLA) en niños
Estudios de sobrevida a la LLA en países de ingreso mediano-alto
Estimación de curvas de sobrevida con el método Kaplan-Meier
Enfermedades
Acute Lymphoid Leukemia (ALL) in Children
Survival studies for ALL in upper-middle-income countries
Estimation of survival curves with the Kaplan-Meier method
title_short Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
title_full Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
title_fullStr Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
title_full_unstemmed Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
title_sort Sobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de Bogotá
dc.contributor.advisor.none.fl_str_mv Garcés Sterling, Sandra Patricia
Vélez van Meerbeke, Alberto Francisco
dc.subject.spa.fl_str_mv Leucemia Linfoide Aguda (LLA) en niños
Estudios de sobrevida a la LLA en países de ingreso mediano-alto
Estimación de curvas de sobrevida con el método Kaplan-Meier
topic Leucemia Linfoide Aguda (LLA) en niños
Estudios de sobrevida a la LLA en países de ingreso mediano-alto
Estimación de curvas de sobrevida con el método Kaplan-Meier
Enfermedades
Acute Lymphoid Leukemia (ALL) in Children
Survival studies for ALL in upper-middle-income countries
Estimation of survival curves with the Kaplan-Meier method
dc.subject.ddc.spa.fl_str_mv Enfermedades
dc.subject.keyword.spa.fl_str_mv Acute Lymphoid Leukemia (ALL) in Children
Survival studies for ALL in upper-middle-income countries
Estimation of survival curves with the Kaplan-Meier method
description Introducción: La Leucemia Linfoide Aguda (LLA) es el cáncer más común en niños. Existen estudios de sobrevida y sus factores asociados en países de altos ingresos, pero pocos en países de ingreso mediano-alto, como Colombia. Objetivo: Establecer la sobrevida global y analizar los factores que inciden en la misma. Materiales y métodos: Estudio descriptivo de serie de casos de niños con LLA tratados en la Fundación Cardioinfantil 2007-2017. Se obtuvo datos de 72 pacientes. Se obtuvo información demográfica, paraclínica, del tratamiento recibido y desenlace en una base de datos. Se estableció la sobrevida global y posteriormente se realizó un análisis con modelo de cohortes para establecer las diferentes variables que la afectaban. Las curvas de sobrevida fueron estimadas con el método Kaplan-Meier. Los factores encontrados se evaluaron mediante el modelo de riesgos proporcionales de Cox. Se obtuvo aprobación del comité de ética. Resultados: La sobrevida a 10 años fue de 73,9%. La LDH al diagnóstico (P= 0,012), clasificación del riesgo (P= 0,013), tratamiento recibido (P= 0,009), no adherencia al tratamiento (P=0,000), necesidad de segundo esquema de tratamiento por recaída (P=0,000) y en el análisis multivariado, la procedencia (P=0,037) la impactaron negativamente. Conclusiones: La sobrevida global es equiparable con centros de referencia nacionales en cáncer infantil. Se requiere la realización de estudios prospectivos en donde se identifiquen nuevos factores de riesgo que expliquen la falla al tratamiento de la LLA pediátrica y que permitan diseñar protocolos de tratamiento cada vez más específicos y tendientes a mejorar la sobrevida de los pacientes.
publishDate 2021
dc.date.accessioned.none.fl_str_mv 2021-02-23T21:21:00Z
dc.date.available.none.fl_str_mv 2021-02-23T21:21:00Z
dc.date.created.none.fl_str_mv 2021-02-05
dc.type.eng.fl_str_mv bachelorThesis
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.document.spa.fl_str_mv Descriptivo observacional retrospectivo
dc.type.spa.spa.fl_str_mv Trabajo de grado
dc.identifier.doi.none.fl_str_mv https://doi.org/10.48713/10336_30971
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/30971
url https://doi.org/10.48713/10336_30971
https://repository.urosario.edu.co/handle/10336/30971
dc.language.iso.spa.fl_str_mv spa
language spa
dc.rights.spa.fl_str_mv Atribución-SinDerivadas 2.5 Colombia
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nd/2.5/co/
rights_invalid_str_mv Atribución-SinDerivadas 2.5 Colombia
Abierto (Texto Completo)
http://creativecommons.org/licenses/by-nd/2.5/co/
http://purl.org/coar/access_right/c_abf2
dc.format.extent.spa.fl_str_mv 61
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad del Rosario
dc.publisher.department.spa.fl_str_mv Escuela de Medicina y Ciencias de la Salud
dc.publisher.program.spa.fl_str_mv Especialización en Pediatría
institution Universidad del Rosario
dc.source.bibliographicCitation.spa.fl_str_mv 1. Fondo Colombiano de Enfermedades de Alto Costo. Generalidades Cáncer Pediátrico. In: Situación del Cáncer en Colombia 2015. Fondo Colombiano de Enfermedades de Alto Costo; 2015. p. 73–90.
2. Bravo LE, García LS, Collazos P, Aristizabal P, Ramírez O. Descriptive epidemiology of childhood cancer in Cali, Colombia 1977-2011. Colomb Med. 2013;44(3):155–64.
3. Coebergh JWW, Reedijk AMJ, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.
4. Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): Based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98(1):74–88.
5. Ries L, Smith M, Gurney J, Linet M, Tamra T, Young J, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. 1999. p. 1–182.
6. Miller R. Persons with exceptionally high risk of leukemia. Cancer Res. 1967;27:2420–2423.
7. Belson M, Kingsley B, Holmes A. Risk Factors for Acute Leukemia in Children: A Review. Environ Health Perspect. 2007;115(1):138–45.
8. Gardner MJ. Father’s occupational exposure to radiation and the raised level of childhood leukemia near the Sellafield nuclear plant. Environ Health Perspect. 1991;94:5–7.
9. McKinney PA, Alexander FE, Cartwright RA, Parker L. Parental Occupations Of Children With Leukaemia In West Cumbria, North Humberside, And Gateshead. Vol. 302, BMJ: British Medical Journal. BMJ; 1991. p. 681–7.
10. Shu XO, Stewart P, Wen W, Han D, Potter JD, Buckley JD, et al. Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring 1. Cancer Epidemiol biomarkers Prev. 1999;8:783–91.
11. Freedman DM, Stewart P, Kleinerman RA, Wacholder S, Hatch EE, Tarone RE, et al. Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health. 2001;91(4):564–7.
12. Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de Cáncer en Colombia 2007-2011. 1st ed. Pardo C, Cendales R, editors. Vol. 1, Instituto Nacional De Cancerologia. Bogotá D.C.; 2015. 13–147 p.
13. Vera AM, Pardo C, Duarte MC, Suárez A. Experiencia en el análisis de la mortalidad por leucemia aguda pediátrica en el Instituto Nacional de Cancerología. Biomédica. 2012;32(3):355–64.
14. Linares Ballesteros A, Torres Amaya AM, Molina León HF, Vizcaíno Valderrama MP, Martínez Beltrán L, de Los Reyes Valencia I del C, et al. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas y adolescentes. Ministerio de Salud y Protección Social - Colciencias; 2013. p. 4–83.
15. World Health Organization. Global Cancer Observatory [Internet]. International Agency for Research on Cancer. 2020 [cited 2021 Feb 4]. Available from: https://gco.iarc.fr/
16. Bosetti C, Bertuccio P, Chatenoud L, Negri E, Levi F, La Vecchia C. Childhood cancer mortality in Europe, 1970-2007. Eur J Cancer. 2010;46(2):384–94.
17. Hunger SP, Winick NJ, Sather HN, Carroll WL. Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough? Pediatr Blood Cancer. 2005;45(7):876–80.
18. Magrath I, Steliarova-foucher E, Epelman S, Ribeiro RC, Harif M, Li C, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14:e104–16.
19. Wayne AS, Reaman GH, Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008;100(18):1271–3.
20. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update. J Clin Oncol. 2011;29(5):551–65.
21. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4–12.
22. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6):992–1005.
23. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.
24. Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Félix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: Prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223–9.
25. Piñeros M, Pardo C, Otero J, Suárez A, Vizcaíno M, Alvarez VH, et al. Protocolo de vigilancia en salud pública de las leucemias agudas pediátricas. Instituto Nacional de Salud Instituto Nacional de Cancerología Ministerio de la Protección social. 2007. p. 1–13.
26. Sarmiento-Urbina IC, Linares-Ballesteros A, Contreras-Acosta A, Cabrera-Bernal EV, Pardo-González CA, Uribe-Botero GI, et al. Resultados del Protocolo ACHOP 2006 en los niños con leucemia linfoblástica aguda en la Fundación HOMI Hospital de la Misericordia de Bogotá, en el periodo 2007 - 2012. IATREIA. 2019;32(2):71–81.
27. Cuenta de Alto Costo. Situación del cáncer de la población atendida en el SGSSS en Colombia 2015. Cuenta Alto Costo. 2016;1(1):35–330.
28. Nordlund J, Syvänen AC. Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol. 2018;51:129–38.
29. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–83.
30. Lanzkowsky P. Leukemias. In: Lanzkowsky P, editor. Manual of Pediatric Hematology and Oncology. 5th ed. San Diego, California: ElSevier; 2011. p. 518–66.
31. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61–73.
32. Instituto Nacional de Cancerología. Protocolo de tratamiento de Leucemia Linfoblástica Aguda LLA - INC 2012 basado en LLA - PINDA IC 2009. 2012. p. 1–42.
33. Erker C, Yan K, Zhang L, Bingen K, Flynn KE, Panepinto J. Impact of pediatric cancer on family relationships. Cancer Med. 2018;7(5):1680–8.
34. Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol. 2017;83(12):2605–14.
35. Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149–65.
36. Turcotte LM, Liu Q, Yasui Y, Arnold MA, Hammond S, Howell RM, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA - J Am Med Assoc. 2017;317(8):814–24.
37. Gaudichon J, Jakobczyk H, Debaize L, Cousin E. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56.
38. Irestorm E, Olsson IT, Johansson B, Øra I. Cognitive fatigue in relation to depressive symptoms after treatment for childhood cancer. BMC Psychol. 2020;8(31):1–9.
39. Steur LMH, Grootenhuis MA, Van Someren EJW, Van Eijkelenburg NKA, Van der Sluis IM, Dors N, et al. High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. Pediatr Blood Cancer. 2020;67(4):e28165.
40. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515–23.
41. The World Bank. World Bank Country and Lending Groups [Internet]. Working for a World Free of Poverty. 2020 [cited 2021 Feb 4]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519
42. Bravo L, Collazos T, García L, Gutiérrez A, Carrascal E. Cáncer infantil en Cali, Colombia, 1994-2003. Registro Poblacional de Cáncer en Cali. Cali: Camilo Torres Serna y Cia S.C.S; 2009.
43. Abboud MR, Ghanem K, Muwakkit S. Acute lymphoblastic leukemia in low and middle-income countries: disease characteristics and treatment results. Curr Opin Oncon. 2014;26(6):650–5.
44. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):1–24.
45. Rengifo LA, Suárez A. Protocolo de tratamiento de leucemia linfoblástica aguda LLA-INC 2012. Basado en LLA-PINDA 2009. Inst Nac Cancerol. 2012;1–42.
46. Campbell M, Luis C, Riccheri C, Janic D, Jazbec J, Kaiserova E, et al. Protocolo de estudio y tratamiento de la leucemia linfoblástica infantil. ALL IC-BFM 2009. Santiago de Chile: Ministerio de Salud de Chile; 2009. p. 1–174.
47. Ospina-Romero M, Portilla CA, Bravo LE, Ramirez O. Caregivers’ self-reported absence of social support networks is related to treatment abandonment in children with cancer. Pediatr Blood Cancer. 2016;63:825–31.
48. Shen S, Cai J, Chen J, Xue H, Pan C, Gao Y, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018;36(July):679–88.
49. Downing JR, Shannon KM. Acute leukemia: A pediatric perspective. Cancer Cell. 2002;2(6):437–45
50. Linet MS, Ries LAG, Smith MA, Robert E, Devesa SS. Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States. J Natl Cancer Institute. 1999;91(12):1051–8.
51. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
52. Hutter JJ. Childhood Leukemia. Pediatr Rev. 2010;31(6):234–41.
53. Hunger S, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–52.
54. Hoshino A, Okuno Y, Migita M, Ban H, Yang X, Kiyokawa N, et al. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. J Clin Immunol. 2015;35(2):108–11.
55. Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66
56. Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4(4):270–90.
57. Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass KK, Devens F, et al. Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia. 2017;31(10):2048–56.
58. Varon R, Reis A, Henze G, Einsiedel HG V., Sperling K, Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 2001;61(9):3570–2.
59. Adams M, Jenney M, Lazarou L, White R, Birdsall S, Staab T, et al. Acute Myeloid Leukaemia after Treatment for Acute Lymphoblastic Leukaemia in Girl with Bloom Syndrome. J Genet Syndr Gene Ther. 2014;4(8):1–12
60. Werner-Favre C, Wyss M, Cabrol C, Felix F, Guenin R, Laufer D. Cytogenetic study in a mentally retarded child with Bloom syndrome and acute lymphoblastic leukemia. Am J Med Genet. 1984;18(2):215–221
61. Wang Y, Sun Z, Xu Y. Carriage of NBN polymorphisms and acute leukemia risk. Int J Clin Exp Med. 2015;8(3):3769–76.
62. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3–4):214–21.
63. Online Mendelinan Inheritance in Man. Fanconi Anemia [Internet]. OMIM. 2019 [cited 2020 Feb 24]. Available from: https://omim.org/search/?index=entry&start=1&limit=10&sort=score+desc%2C+prefix_sort+desc&search=Fanconi+anemia
64. Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591–9.
65. Zawitkowska J, Odoj T, Drabko K, Zaucha-Prazmo A, Rudnicka J, Romiszewski M, et al. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report. Pediatr Hematol Oncol. 2017;34(4):1–8.
66. Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013;105(10):733–42.
67. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62.
68. Kinlen L. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer. 1995;71:1–5.
69. Bartenhagen C, Fischer U, Korn K, Pfister SM, Gombert M, Chen C, et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102(5):e179–83.
70. Martín-Lorenzo A, Hauer J, Vicente-Dueñas C, Auer F, González-Herrero I, García-Ramírez I, et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. Cancer Discov. 2015;5(12):1328–43.
71. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193–203
72. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia. 1993 Mar;7(3):349–60.
73. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon S-M, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015;16(7):766–74
74. Baljevic M, Jabbour E, O’Brien S, Kantarjian H. Acute Lymphoblastic Leukemia. In: Kantarjian H, Wolff R, editors. The MD Anderson Manual of Medical Oncology. 3rd ed. New York City: McGraw-Hill; 2016.
75. Margolin JF, Steuber P, Poplack DG. Acute Lymphoblastic Leukemia. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott-Williams and Wilkins; 2006.
76. Robazzi TCMV, Silva LR, Mendonça N, Barreto JHS. Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents. Acta Gastroenterol Latinoam. 2008;38(2):126–32.
77. Stephanos K, Picard L. Pediatric Oncologic Emergencies. Emerg Med Clin N Am. 2018;36(3):527–35.
78. Margolin J, Rabin K, Steuber P, Poplack D. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, editors. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2011. p. 518–65
79. Hangai M, Watanabe K, Shiozawa R, Hiwatari M, Ida K, Takita J. Relapsed acute lymphoblastic leukemia with unusual multiple bone invasions: A case report. Oncol Lett. 2014;7(4):991–3.
80. Sherief LM, Azab SF, Zakaria MM, Kamal M, Aly MAE, Ali A, et al. Renal presentation in pediatric acute leukemia: Report of 2 cases. Med (United States). 2015;94(37):37–40.
81. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol. 2008;129(1):130–42.
82. Jarošová M, Holzerová M, Jedličková K, Mihál V, Zuna J, Starý J, et al. Importance of using comparative genomic hybridization to improve detection of chromosomal changes in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000;123(2):114–22.
83. Mrózek K, Harper DP, Aplan PD. Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2009;23(5):991–1010.
84. Sutor A, Mall V, Thomas K. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Pädiatrie. 1999 Jul 13;211(04):201–4
85. Lauer S, Kirchner P, Camitta B. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Am J Pediatr Hematol Oncol. 1989;11(1):64–73.
86. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al. Low leucocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329(5):314–9.
87. McIntosh S, Ritchey A. Diagnostic problems in cerebrospinal fluid of children with lymphoid malignancies. Am J Pediatr Hematol Oncol. 1986;8(1):28–31
88. Ingram LC, Fairclough DL, Furman WL, Sandlund JT, Kun LE, Rivera GK, et al. Cranial nerve palsy in childhood acute lymphoblastic leukemia and non‐Hodgkin’s lymphoma. Cancer. 1991;67(9):2262–8.
89. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24.
90. Gilchrist GS, Tubergen DG, Sather HN, Coccia PF, O’Brien RT, Waskerwitz MJ, et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol. 1994;12(12):2594–600.
91. Tubergen DG, Cullen JW, Boyett JM, Gilchrist GS, O’Brien RT, Coccia PF, et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group study. J Clin Oncol. 1994;12(2):273–8.
92. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003 May 1;21(9):1798–809.
93. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton D, Gralnick H, et al. (FAB Co- operative Group): Proposals for the classification of the acute leukaemias. Br J Haematol. 1976;33:451.
94. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton D, Gralnick H, et al. (FAB Co- operative Group): The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol. 1981;47:553.
95. Linares-Ballesteros A. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas ya dolescentes. Ministerio de Salud y Protección Social; 2013.
96. Vizcaino M, Lopera J, Martínez L, De los Reyes I, Linares A. Clinical practice guidelines for early detection, diagnosis, treatment and monitoring of acute lymcytic leukemia in children and teenagers in a developing country. Pediatr Infect Dis Open Access. 2016;1(4):25.
97. Langebrake C, Reinhardt D, Ritter J. Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf. 2002;25(15):1057–77.
98. Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT, et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14(7):1185–90.
99. Zawitkowska J, Lejman M, Zaucha-Prazmo A, Drabko K, Plonowski M, Bulsa J, et al. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia. In Vivo (Brooklyn). 2019;33:1333–9.
100. Krull KR. Dexamethasone and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(3):e28118.
101. Mulhern R, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, et al. Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status. J Clin Oncol. 1992;(10):1095–1102.
102. Mulhern R, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol1. 1991;(9):1348–1356.
103. Tanner J, Davies P. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317–329.
104. Marshall W, Tanner J. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;13–23.
105. Marshall W, Tanner J. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;291–303.
106. Schmiegelow K, Müller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Research. 2017;6(444):1–14.
107. Halsey C, Buck G, Richards S, Vargha-khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4(1):42.
108. Waber DP, Mccabe M, Sebree M, Forbes PW, Adams H, Alyman C, et al. Neuropsychological Outcomes of a Randomized Trial of Prednisone Versus Dexamethasone in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2013;60:1785–91.
109. Sun Y, Long S, Liu W. Observation of the molecular genetics among children with acute lymphoblastic leukemia: A retrospective study based on the SEER database. Medicine (Baltimore). 2020;99(21):e20009.
110. Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56:551–9.
111. Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672–6.
112. Pui C, Rebora P, Schrappe M, Attarbaschi A, Baruchel A. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019;37(10):770–9.
113. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL -rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–7.
114. Schultz K, Carroll A, Heeerema N, Bowman W, Slayton W, Sather H, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467–71.
115. Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: A report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol. 2010;34(6):659–66.
116. Barr RD, Klussman FA, Baez F, Bonilla M, Moreno B, Navarrete M, et al. Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A Model for Sustainable Development in Pediatric Oncology. Pediatr Blood Cancer. 2014;61:345–54.
117. Suarez A, Piña M, Nichols-Vinueza DX, Lopera J, Rengifo L, Mesa M, et al. A Strategy to Improve Treatment-Related Mortality and Abandonment of Therapy for Childhood ALL in a Developing Country Reveals the Impact of Treatment Delays. Pediatr Blood Cancer. 2015;62(March):1395–402.
118. Freeman D. Applied categorical data analysis. New York: Dekker, Inc; 1987.
119. RAE. Real Academia Española [Internet]. 2018 [cited 2018 Sep 21]. Available from: http://dle.rae.es/?id=XlApmpe
120. De la Asociación Médica Mundial sobre principios éticos para las investigaciones médicas en seres humanos. Declaración de Helsinki. 59a Asamblea General. 2008.
121. Ministerio de Salud. Resolución 8430 de 1993. Colombia; 1993 p. 1–19.
122. Congreso de Colombia. Ley estatutaria No. 1581. 17 Octubre 2012. Colombia; 2012 p. 1–301.
123. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):3206–14.
124. Campbell M. ALL IC-BFM 2009 A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia. 2009. 178 p.
125. Malo D, Pulido A. Infección Respiratoria Aguda, Colombia 2017. Instituto Nacional de Salud. 2017. p. 1–31.
126. Bartenhagen C, Fischer U, Korn K, Pfister S, Gombert M, Chen C, et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102:e179.
127. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.
128. Pui C-H, Dodge RK, Dahl G V, Rivera G, Look AT, Kalwinsky D, et al. Serum Lactic Dehydrogenase Level Has Prognostic Value in Childhoold Acute Lymphoblastic Leukemia. Blood. 1985;66(4):778–82.
129. Murali N, Swamy M, Prasad H, Saha D, Kini J, Kumar N. Significance of serum lactate dehydrogenase in childhood acute Lymphoblastic Leukaemia. J Clin Diagnostic Res. 2017;11(11):XC01–2.
130. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.
131. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958–66.
132. Ramot B, Magrath I. Hypothesis: the environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukaemia in children. Br J Haematol. 1982;50(2):183–9.
133. Filippini T, Hatch EE, Rothman KJ, Heck JE, Park AS, Crippa A, et al. Association between Outdoor Air Pollution and Childhood Leukemia: A Systematic Review and Dose-Response Meta-Analysis. Environ Health Perspect. 2019;127(4):46002.
134. Wakeford R. Childhood leukemia following medical diagnostic exposre to ionizing radiation in utero or after birth. Radiat Prot Dosimetry. 2008;132(2):166–74.
135. Cangerana F, Mirra A, Dias de Oliveira M do R, de Assunção JV. Environmental Risk Factors and Acute Lymphoblastic Leukaemia in Childhood. Rev Cienc Salud. 2017;15(1):129–44.
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv https://repository.urosario.edu.co/bitstreams/b5187c33-96fd-4166-a659-5348a99bc77b/download
https://repository.urosario.edu.co/bitstreams/391f6c21-2fc0-4da5-9dcc-f1770f1ef90e/download
https://repository.urosario.edu.co/bitstreams/33d53ff6-ee15-427e-bd62-34b2c244e297/download
https://repository.urosario.edu.co/bitstreams/e984ca19-fb43-4da6-a0ff-841f48d5abf6/download
https://repository.urosario.edu.co/bitstreams/ca1e0b94-de17-424d-8e37-c03c07d2d23e/download
bitstream.checksum.fl_str_mv e2b73c447512f75c2a0464d910792edd
fab9d9ed61d64f6ac005dee3306ae77e
dab767be7a093b539031785b3bf95490
e1037f6ece5f1e28c0a58aeec881703a
f5c6831c7ab2514049074d30195ca7ba
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1808390905376276480
spelling Garcés Sterling, Sandra Patriciaef8e510e-06f1-4322-8d0c-bc3017acc7b3600Vélez van Meerbeke, Alberto Francisco79141398600Castelblanco-Coy, Lizeth JohanaEspecialista en PediatríaFull time0543d733-293f-469b-bda9-0fddac79e7496002021-02-23T21:21:00Z2021-02-23T21:21:00Z2021-02-05Introducción: La Leucemia Linfoide Aguda (LLA) es el cáncer más común en niños. Existen estudios de sobrevida y sus factores asociados en países de altos ingresos, pero pocos en países de ingreso mediano-alto, como Colombia. Objetivo: Establecer la sobrevida global y analizar los factores que inciden en la misma. Materiales y métodos: Estudio descriptivo de serie de casos de niños con LLA tratados en la Fundación Cardioinfantil 2007-2017. Se obtuvo datos de 72 pacientes. Se obtuvo información demográfica, paraclínica, del tratamiento recibido y desenlace en una base de datos. Se estableció la sobrevida global y posteriormente se realizó un análisis con modelo de cohortes para establecer las diferentes variables que la afectaban. Las curvas de sobrevida fueron estimadas con el método Kaplan-Meier. Los factores encontrados se evaluaron mediante el modelo de riesgos proporcionales de Cox. Se obtuvo aprobación del comité de ética. Resultados: La sobrevida a 10 años fue de 73,9%. La LDH al diagnóstico (P= 0,012), clasificación del riesgo (P= 0,013), tratamiento recibido (P= 0,009), no adherencia al tratamiento (P=0,000), necesidad de segundo esquema de tratamiento por recaída (P=0,000) y en el análisis multivariado, la procedencia (P=0,037) la impactaron negativamente. Conclusiones: La sobrevida global es equiparable con centros de referencia nacionales en cáncer infantil. Se requiere la realización de estudios prospectivos en donde se identifiquen nuevos factores de riesgo que expliquen la falla al tratamiento de la LLA pediátrica y que permitan diseñar protocolos de tratamiento cada vez más específicos y tendientes a mejorar la sobrevida de los pacientes.Introduction: Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children. There are several studies in high-income countries regarding survival rate and its associated factors, but studies are lacking in upper-middle income countries, like Colombia. Objective: To establish the overall survival rate and to analyze its associated factors that negatively impact it. Methods: A descriptive case study of children with Acute Lymphoblastic Leukemia who were treated at Fundación Cardioinfantil from 2007-2017 was carried out. Data obtained from case records of 72 patients was analyzed. Information regarding demographic profile, labs on diagnosis, treatment, and outcome were recorded on a database. Overall survival rate was determined and a cohort analysis was used to establish which factors affected it. Survival curves were estimated using the Kaplan–Meier method. Associated factors were assessed using Cox Proportional Hazards Regression Analysis. The study was approved by the ethics committee. Results: Overall 10-year survival rate was 73.9%. LDH on diagnosis (P= 0,012), risk stratification (P= 0,013), treatment administered (P= 0,009), non adherence to treatment (P=0,000), second course of treatment due to relapse (P=0,000) and on multivariate analysis urban areas of origin (P=0,037) negatively impacted survival rate. Conclusions: Overall survival rate is comparable to national pediatric cancer reference centers. Future prospective studies that recognize other associated factors that potentially explain treatment failure are needed. This will enable new randomized controlled trials that may evaluate different and more targeted treatment protocols that Will improve overall survival rates in children with ALL.61application/pdfBogotá, Colombiahttps://doi.org/10.48713/10336_30971https://repository.urosario.edu.co/handle/10336/30971spaUniversidad del RosarioEscuela de Medicina y Ciencias de la SaludEspecialización en PediatríaAtribución-SinDerivadas 2.5 ColombiaAbierto (Texto Completo)EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.http://creativecommons.org/licenses/by-nd/2.5/co/http://purl.org/coar/access_right/c_abf21. Fondo Colombiano de Enfermedades de Alto Costo. Generalidades Cáncer Pediátrico. In: Situación del Cáncer en Colombia 2015. Fondo Colombiano de Enfermedades de Alto Costo; 2015. p. 73–90.2. Bravo LE, García LS, Collazos P, Aristizabal P, Ramírez O. Descriptive epidemiology of childhood cancer in Cali, Colombia 1977-2011. Colomb Med. 2013;44(3):155–64.3. Coebergh JWW, Reedijk AMJ, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.4. Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): Based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98(1):74–88.5. Ries L, Smith M, Gurney J, Linet M, Tamra T, Young J, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. 1999. p. 1–182.6. Miller R. Persons with exceptionally high risk of leukemia. Cancer Res. 1967;27:2420–2423.7. Belson M, Kingsley B, Holmes A. Risk Factors for Acute Leukemia in Children: A Review. Environ Health Perspect. 2007;115(1):138–45.8. Gardner MJ. Father’s occupational exposure to radiation and the raised level of childhood leukemia near the Sellafield nuclear plant. Environ Health Perspect. 1991;94:5–7.9. McKinney PA, Alexander FE, Cartwright RA, Parker L. Parental Occupations Of Children With Leukaemia In West Cumbria, North Humberside, And Gateshead. Vol. 302, BMJ: British Medical Journal. BMJ; 1991. p. 681–7.10. Shu XO, Stewart P, Wen W, Han D, Potter JD, Buckley JD, et al. Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring Parental Occupational Exposure to Hydrocarbons and Risk of Acute Lymphocytic Leukemia in Offspring 1. Cancer Epidemiol biomarkers Prev. 1999;8:783–91.11. Freedman DM, Stewart P, Kleinerman RA, Wacholder S, Hatch EE, Tarone RE, et al. Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health. 2001;91(4):564–7.12. Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de Cáncer en Colombia 2007-2011. 1st ed. Pardo C, Cendales R, editors. Vol. 1, Instituto Nacional De Cancerologia. Bogotá D.C.; 2015. 13–147 p.13. Vera AM, Pardo C, Duarte MC, Suárez A. Experiencia en el análisis de la mortalidad por leucemia aguda pediátrica en el Instituto Nacional de Cancerología. Biomédica. 2012;32(3):355–64.14. Linares Ballesteros A, Torres Amaya AM, Molina León HF, Vizcaíno Valderrama MP, Martínez Beltrán L, de Los Reyes Valencia I del C, et al. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas y adolescentes. Ministerio de Salud y Protección Social - Colciencias; 2013. p. 4–83.15. World Health Organization. Global Cancer Observatory [Internet]. International Agency for Research on Cancer. 2020 [cited 2021 Feb 4]. Available from: https://gco.iarc.fr/16. Bosetti C, Bertuccio P, Chatenoud L, Negri E, Levi F, La Vecchia C. Childhood cancer mortality in Europe, 1970-2007. Eur J Cancer. 2010;46(2):384–94.17. Hunger SP, Winick NJ, Sather HN, Carroll WL. Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough? Pediatr Blood Cancer. 2005;45(7):876–80.18. Magrath I, Steliarova-foucher E, Epelman S, Ribeiro RC, Harif M, Li C, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14:e104–16.19. Wayne AS, Reaman GH, Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008;100(18):1271–3.20. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update. J Clin Oncol. 2011;29(5):551–65.21. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4–12.22. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6):992–1005.23. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.24. Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Félix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: Prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223–9.25. Piñeros M, Pardo C, Otero J, Suárez A, Vizcaíno M, Alvarez VH, et al. Protocolo de vigilancia en salud pública de las leucemias agudas pediátricas. Instituto Nacional de Salud Instituto Nacional de Cancerología Ministerio de la Protección social. 2007. p. 1–13.26. Sarmiento-Urbina IC, Linares-Ballesteros A, Contreras-Acosta A, Cabrera-Bernal EV, Pardo-González CA, Uribe-Botero GI, et al. Resultados del Protocolo ACHOP 2006 en los niños con leucemia linfoblástica aguda en la Fundación HOMI Hospital de la Misericordia de Bogotá, en el periodo 2007 - 2012. IATREIA. 2019;32(2):71–81.27. Cuenta de Alto Costo. Situación del cáncer de la población atendida en el SGSSS en Colombia 2015. Cuenta Alto Costo. 2016;1(1):35–330.28. Nordlund J, Syvänen AC. Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol. 2018;51:129–38.29. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–83.30. Lanzkowsky P. Leukemias. In: Lanzkowsky P, editor. Manual of Pediatric Hematology and Oncology. 5th ed. San Diego, California: ElSevier; 2011. p. 518–66.31. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61–73.32. Instituto Nacional de Cancerología. Protocolo de tratamiento de Leucemia Linfoblástica Aguda LLA - INC 2012 basado en LLA - PINDA IC 2009. 2012. p. 1–42.33. Erker C, Yan K, Zhang L, Bingen K, Flynn KE, Panepinto J. Impact of pediatric cancer on family relationships. Cancer Med. 2018;7(5):1680–8.34. Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi R. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol. 2017;83(12):2605–14.35. Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149–65.36. Turcotte LM, Liu Q, Yasui Y, Arnold MA, Hammond S, Howell RM, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA - J Am Med Assoc. 2017;317(8):814–24.37. Gaudichon J, Jakobczyk H, Debaize L, Cousin E. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56.38. Irestorm E, Olsson IT, Johansson B, Øra I. Cognitive fatigue in relation to depressive symptoms after treatment for childhood cancer. BMC Psychol. 2020;8(31):1–9.39. Steur LMH, Grootenhuis MA, Van Someren EJW, Van Eijkelenburg NKA, Van der Sluis IM, Dors N, et al. High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. Pediatr Blood Cancer. 2020;67(4):e28165.40. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515–23.41. The World Bank. World Bank Country and Lending Groups [Internet]. Working for a World Free of Poverty. 2020 [cited 2021 Feb 4]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/90651942. Bravo L, Collazos T, García L, Gutiérrez A, Carrascal E. Cáncer infantil en Cali, Colombia, 1994-2003. Registro Poblacional de Cáncer en Cali. Cali: Camilo Torres Serna y Cia S.C.S; 2009.43. Abboud MR, Ghanem K, Muwakkit S. Acute lymphoblastic leukemia in low and middle-income countries: disease characteristics and treatment results. Curr Opin Oncon. 2014;26(6):650–5.44. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):1–24.45. Rengifo LA, Suárez A. Protocolo de tratamiento de leucemia linfoblástica aguda LLA-INC 2012. Basado en LLA-PINDA 2009. Inst Nac Cancerol. 2012;1–42.46. Campbell M, Luis C, Riccheri C, Janic D, Jazbec J, Kaiserova E, et al. Protocolo de estudio y tratamiento de la leucemia linfoblástica infantil. ALL IC-BFM 2009. Santiago de Chile: Ministerio de Salud de Chile; 2009. p. 1–174.47. Ospina-Romero M, Portilla CA, Bravo LE, Ramirez O. Caregivers’ self-reported absence of social support networks is related to treatment abandonment in children with cancer. Pediatr Blood Cancer. 2016;63:825–31.48. Shen S, Cai J, Chen J, Xue H, Pan C, Gao Y, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018;36(July):679–88.49. Downing JR, Shannon KM. Acute leukemia: A pediatric perspective. Cancer Cell. 2002;2(6):437–4550. Linet MS, Ries LAG, Smith MA, Robert E, Devesa SS. Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States. J Natl Cancer Institute. 1999;91(12):1051–8.51. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.52. Hutter JJ. Childhood Leukemia. Pediatr Rev. 2010;31(6):234–41.53. Hunger S, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–52.54. Hoshino A, Okuno Y, Migita M, Ban H, Yang X, Kiyokawa N, et al. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. J Clin Immunol. 2015;35(2):108–11.55. Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–6656. Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4(4):270–90.57. Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass KK, Devens F, et al. Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia. 2017;31(10):2048–56.58. Varon R, Reis A, Henze G, Einsiedel HG V., Sperling K, Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 2001;61(9):3570–2.59. Adams M, Jenney M, Lazarou L, White R, Birdsall S, Staab T, et al. Acute Myeloid Leukaemia after Treatment for Acute Lymphoblastic Leukaemia in Girl with Bloom Syndrome. J Genet Syndr Gene Ther. 2014;4(8):1–1260. Werner-Favre C, Wyss M, Cabrol C, Felix F, Guenin R, Laufer D. Cytogenetic study in a mentally retarded child with Bloom syndrome and acute lymphoblastic leukemia. Am J Med Genet. 1984;18(2):215–22161. Wang Y, Sun Z, Xu Y. Carriage of NBN polymorphisms and acute leukemia risk. Int J Clin Exp Med. 2015;8(3):3769–76.62. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3–4):214–21.63. Online Mendelinan Inheritance in Man. Fanconi Anemia [Internet]. OMIM. 2019 [cited 2020 Feb 24]. Available from: https://omim.org/search/?index=entry&start=1&limit=10&sort=score+desc%2C+prefix_sort+desc&search=Fanconi+anemia64. Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591–9.65. Zawitkowska J, Odoj T, Drabko K, Zaucha-Prazmo A, Rudnicka J, Romiszewski M, et al. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report. Pediatr Hematol Oncol. 2017;34(4):1–8.66. Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013;105(10):733–42.67. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62.68. Kinlen L. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer. 1995;71:1–5.69. Bartenhagen C, Fischer U, Korn K, Pfister SM, Gombert M, Chen C, et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102(5):e179–83.70. Martín-Lorenzo A, Hauer J, Vicente-Dueñas C, Auer F, González-Herrero I, García-Ramírez I, et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. Cancer Discov. 2015;5(12):1328–43.71. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193–20372. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia. 1993 Mar;7(3):349–60.73. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon S-M, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol. 2015;16(7):766–7474. Baljevic M, Jabbour E, O’Brien S, Kantarjian H. Acute Lymphoblastic Leukemia. In: Kantarjian H, Wolff R, editors. The MD Anderson Manual of Medical Oncology. 3rd ed. New York City: McGraw-Hill; 2016.75. Margolin JF, Steuber P, Poplack DG. Acute Lymphoblastic Leukemia. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott-Williams and Wilkins; 2006.76. Robazzi TCMV, Silva LR, Mendonça N, Barreto JHS. Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents. Acta Gastroenterol Latinoam. 2008;38(2):126–32.77. Stephanos K, Picard L. Pediatric Oncologic Emergencies. Emerg Med Clin N Am. 2018;36(3):527–35.78. Margolin J, Rabin K, Steuber P, Poplack D. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, editors. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2011. p. 518–6579. Hangai M, Watanabe K, Shiozawa R, Hiwatari M, Ida K, Takita J. Relapsed acute lymphoblastic leukemia with unusual multiple bone invasions: A case report. Oncol Lett. 2014;7(4):991–3.80. Sherief LM, Azab SF, Zakaria MM, Kamal M, Aly MAE, Ali A, et al. Renal presentation in pediatric acute leukemia: Report of 2 cases. Med (United States). 2015;94(37):37–40.81. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol. 2008;129(1):130–42.82. Jarošová M, Holzerová M, Jedličková K, Mihál V, Zuna J, Starý J, et al. Importance of using comparative genomic hybridization to improve detection of chromosomal changes in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000;123(2):114–22.83. Mrózek K, Harper DP, Aplan PD. Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2009;23(5):991–1010.84. Sutor A, Mall V, Thomas K. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol. Klin Pädiatrie. 1999 Jul 13;211(04):201–485. Lauer S, Kirchner P, Camitta B. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Am J Pediatr Hematol Oncol. 1989;11(1):64–73.86. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al. Low leucocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329(5):314–9.87. McIntosh S, Ritchey A. Diagnostic problems in cerebrospinal fluid of children with lymphoid malignancies. Am J Pediatr Hematol Oncol. 1986;8(1):28–3188. Ingram LC, Fairclough DL, Furman WL, Sandlund JT, Kun LE, Rivera GK, et al. Cranial nerve palsy in childhood acute lymphoblastic leukemia and non‐Hodgkin’s lymphoma. Cancer. 1991;67(9):2262–8.89. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24.90. Gilchrist GS, Tubergen DG, Sather HN, Coccia PF, O’Brien RT, Waskerwitz MJ, et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol. 1994;12(12):2594–600.91. Tubergen DG, Cullen JW, Boyett JM, Gilchrist GS, O’Brien RT, Coccia PF, et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group study. J Clin Oncol. 1994;12(2):273–8.92. Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003 May 1;21(9):1798–809.93. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton D, Gralnick H, et al. (FAB Co- operative Group): Proposals for the classification of the acute leukaemias. Br J Haematol. 1976;33:451.94. Bennett J, Catovsky D, Daniel M-T, Flandrin G, Galton D, Gralnick H, et al. (FAB Co- operative Group): The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol. 1981;47:553.95. Linares-Ballesteros A. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas ya dolescentes. Ministerio de Salud y Protección Social; 2013.96. Vizcaino M, Lopera J, Martínez L, De los Reyes I, Linares A. Clinical practice guidelines for early detection, diagnosis, treatment and monitoring of acute lymcytic leukemia in children and teenagers in a developing country. Pediatr Infect Dis Open Access. 2016;1(4):25.97. Langebrake C, Reinhardt D, Ritter J. Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf. 2002;25(15):1057–77.98. Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT, et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14(7):1185–90.99. Zawitkowska J, Lejman M, Zaucha-Prazmo A, Drabko K, Plonowski M, Bulsa J, et al. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia. In Vivo (Brooklyn). 2019;33:1333–9.100. Krull KR. Dexamethasone and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(3):e28118.101. Mulhern R, Kovnar E, Langston J, Carter M, Fairclough D, Leigh L, et al. Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status. J Clin Oncol. 1992;(10):1095–1102.102. Mulhern R, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol1. 1991;(9):1348–1356.103. Tanner J, Davies P. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317–329.104. Marshall W, Tanner J. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;13–23.105. Marshall W, Tanner J. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;291–303.106. Schmiegelow K, Müller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Research. 2017;6(444):1–14.107. Halsey C, Buck G, Richards S, Vargha-khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J Hematol Oncol. 2011;4(1):42.108. Waber DP, Mccabe M, Sebree M, Forbes PW, Adams H, Alyman C, et al. Neuropsychological Outcomes of a Randomized Trial of Prednisone Versus Dexamethasone in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2013;60:1785–91.109. Sun Y, Long S, Liu W. Observation of the molecular genetics among children with acute lymphoblastic leukemia: A retrospective study based on the SEER database. Medicine (Baltimore). 2020;99(21):e20009.110. Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56:551–9.111. Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672–6.112. Pui C, Rebora P, Schrappe M, Attarbaschi A, Baruchel A. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019;37(10):770–9.113. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL -rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–7.114. Schultz K, Carroll A, Heeerema N, Bowman W, Slayton W, Sather H, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467–71.115. Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: A report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol. 2010;34(6):659–66.116. Barr RD, Klussman FA, Baez F, Bonilla M, Moreno B, Navarrete M, et al. Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A Model for Sustainable Development in Pediatric Oncology. Pediatr Blood Cancer. 2014;61:345–54.117. Suarez A, Piña M, Nichols-Vinueza DX, Lopera J, Rengifo L, Mesa M, et al. A Strategy to Improve Treatment-Related Mortality and Abandonment of Therapy for Childhood ALL in a Developing Country Reveals the Impact of Treatment Delays. Pediatr Blood Cancer. 2015;62(March):1395–402.118. Freeman D. Applied categorical data analysis. New York: Dekker, Inc; 1987.119. RAE. Real Academia Española [Internet]. 2018 [cited 2018 Sep 21]. Available from: http://dle.rae.es/?id=XlApmpe120. De la Asociación Médica Mundial sobre principios éticos para las investigaciones médicas en seres humanos. Declaración de Helsinki. 59a Asamblea General. 2008.121. Ministerio de Salud. Resolución 8430 de 1993. Colombia; 1993 p. 1–19.122. Congreso de Colombia. Ley estatutaria No. 1581. 17 Octubre 2012. Colombia; 2012 p. 1–301.123. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115(16):3206–14.124. Campbell M. ALL IC-BFM 2009 A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia. 2009. 178 p.125. Malo D, Pulido A. Infección Respiratoria Aguda, Colombia 2017. Instituto Nacional de Salud. 2017. p. 1–31.126. Bartenhagen C, Fischer U, Korn K, Pfister S, Gombert M, Chen C, et al. Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. Haematologica. 2017;102:e179.127. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.128. Pui C-H, Dodge RK, Dahl G V, Rivera G, Look AT, Kalwinsky D, et al. Serum Lactic Dehydrogenase Level Has Prognostic Value in Childhoold Acute Lymphoblastic Leukemia. Blood. 1985;66(4):778–82.129. Murali N, Swamy M, Prasad H, Saha D, Kini J, Kumar N. Significance of serum lactate dehydrogenase in childhood acute Lymphoblastic Leukaemia. J Clin Diagnostic Res. 2017;11(11):XC01–2.130. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.131. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958–66.132. Ramot B, Magrath I. Hypothesis: the environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukaemia in children. Br J Haematol. 1982;50(2):183–9.133. Filippini T, Hatch EE, Rothman KJ, Heck JE, Park AS, Crippa A, et al. Association between Outdoor Air Pollution and Childhood Leukemia: A Systematic Review and Dose-Response Meta-Analysis. Environ Health Perspect. 2019;127(4):46002.134. Wakeford R. Childhood leukemia following medical diagnostic exposre to ionizing radiation in utero or after birth. Radiat Prot Dosimetry. 2008;132(2):166–74.135. Cangerana F, Mirra A, Dias de Oliveira M do R, de Assunção JV. Environmental Risk Factors and Acute Lymphoblastic Leukaemia in Childhood. Rev Cienc Salud. 2017;15(1):129–44.instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURLeucemia Linfoide Aguda (LLA) en niñosEstudios de sobrevida a la LLA en países de ingreso mediano-altoEstimación de curvas de sobrevida con el método Kaplan-MeierEnfermedades616600Acute Lymphoid Leukemia (ALL) in ChildrenSurvival studies for ALL in upper-middle-income countriesEstimation of survival curves with the Kaplan-Meier methodSobrevida y factores asociados en niños con Leucemia Linfoide Aguda en un centro de referencia de BogotáSurvival and associated factors in children with Acute Lymphoid Leukemia in a reference center in BogotábachelorThesisDescriptivo observacional retrospectivoTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1fORIGINALCastelblancoCoy-Lizeth-Johana-2021.pdfCastelblancoCoy-Lizeth-Johana-2021.pdfapplication/pdf832066https://repository.urosario.edu.co/bitstreams/b5187c33-96fd-4166-a659-5348a99bc77b/downloade2b73c447512f75c2a0464d910792eddMD51LICENSElicense.txtlicense.txttext/plain1475https://repository.urosario.edu.co/bitstreams/391f6c21-2fc0-4da5-9dcc-f1770f1ef90e/downloadfab9d9ed61d64f6ac005dee3306ae77eMD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://repository.urosario.edu.co/bitstreams/33d53ff6-ee15-427e-bd62-34b2c244e297/downloaddab767be7a093b539031785b3bf95490MD53TEXTCastelblancoCoy-Lizeth-Johana-2021.pdf.txtCastelblancoCoy-Lizeth-Johana-2021.pdf.txtExtracted texttext/plain110112https://repository.urosario.edu.co/bitstreams/e984ca19-fb43-4da6-a0ff-841f48d5abf6/downloade1037f6ece5f1e28c0a58aeec881703aMD54THUMBNAILCastelblancoCoy-Lizeth-Johana-2021.pdf.jpgCastelblancoCoy-Lizeth-Johana-2021.pdf.jpgGenerated Thumbnailimage/jpeg2465https://repository.urosario.edu.co/bitstreams/ca1e0b94-de17-424d-8e37-c03c07d2d23e/downloadf5c6831c7ab2514049074d30195ca7baMD5510336/30971oai:repository.urosario.edu.co:10336/309712022-11-03 10:33:26.638http://creativecommons.org/licenses/by-nd/2.5/co/Atribución-SinDerivadas 2.5 Colombiahttps://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.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

Publicaciones similares